Change in Second-Order Rate Constants of fXa Inhibition
Active Form . | α-Antithrombin . | β-Antithrombin . | ||||
---|---|---|---|---|---|---|
− Heparin (mmol/L−1s−1) . | + Heparin (mmol/L−1s−1) . | − Heparin (mmol/L−1s−1) . | + Heparin (mmol/L−1s−1) . | L:β, 10:1 (mmol/L−1s−1) . | 10:1, + Heparin (mmol/L−1s−1) . | |
(as) Monomer | 3.75 ± 0.01 | 2,170 ± 190 | 7.16 ± 0.15 | 2,410 ± 180 | 7.16 ± 0.15 | 2,410 ± 180 |
(in) Dimer | 3.34 ± 0.08 | 1,720 ± 160 | 5.65 ± 0.05 | 1,630 ± 130 | 3.79 ± 0.15 | 843 ± 33 |
Activity loss | 11% | 21% | 21% | 33% | 47% | 65% |
Active Form . | α-Antithrombin . | β-Antithrombin . | ||||
---|---|---|---|---|---|---|
− Heparin (mmol/L−1s−1) . | + Heparin (mmol/L−1s−1) . | − Heparin (mmol/L−1s−1) . | + Heparin (mmol/L−1s−1) . | L:β, 10:1 (mmol/L−1s−1) . | 10:1, + Heparin (mmol/L−1s−1) . | |
(as) Monomer | 3.75 ± 0.01 | 2,170 ± 190 | 7.16 ± 0.15 | 2,410 ± 180 | 7.16 ± 0.15 | 2,410 ± 180 |
(in) Dimer | 3.34 ± 0.08 | 1,720 ± 160 | 5.65 ± 0.05 | 1,630 ± 130 | 3.79 ± 0.15 | 843 ± 33 |
Activity loss | 11% | 21% | 21% | 33% | 47% | 65% |